Zacks Investment Research·Oct 12, 2026
PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowPMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
PMV Pharmaceuticals remains a pre-revenue biotechnology firm entirely dependent on external financing to sustain its PC14586 Phase 2 PYRENE clinical trial. The company's financial profile is characterized by significant asset erosion, with total assets declining from $252.2 million in 2023Q4 to $96.6 million in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.34+12.3% vs -$0.39 | — vs — |
Q2 2026 May 12, 2026 | -$0.34+17.1% vs -$0.41 | — vs — |
Q2 2026 Mar 6, 2026 | -$0.34+15.0% vs -$0.40 | — vs — |
Q4 2025 Nov 12, 2025 | -$0.40+0.0% vs -$0.40 | — vs — |
PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt's 46% response rate and 10-month median duration in Y220C-mutant ovarian cancer. PMVP's medicinal chemistry leverages the Y220C mutation to stabilize p53, translating into consistent clinical activity across heavily pretreated patients. Risks include a limited initial market, acquired resistance, significant dilution from recent financings, and pivotal Phase 2 data due in Q4 2026.
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating
PMV Pharmaceuticals, Inc. (PMVP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PMVP's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Benchmark PMVP against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PMV Pharmaceuticals, Inc. (PMVP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.26 | $67.2M | -0.89 | — | — | -78.11% | — | |
| $0.50 | $5.02M | -0.33 | — | -112028.8% | — | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $21.50 | $3.5B | -26.04 | 48.29% | -229.92% | -25.74% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — |
PMV Pharmaceuticals, Inc. (PMVP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PMV Pharmaceuticals, Inc. (PMVP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 31, 2026·SEC
Aug 14, 2026·SEC
Jun 5, 2026·SEC
Get notified when PMVP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PMV Pharmaceuticals, Inc. (PMVP) stock FAQ — growth, dividends, profitability & financials explained
No. PMV Pharmaceuticals, Inc. (PMVP) reported a net loss of $75.2M over the trailing twelve months.
PMV Pharmaceuticals, Inc. (PMVP) had a return on equity (ROE) of -78.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
PMV Pharmaceuticals, Inc. (PMVP) had negative free cash flow of $71.3M over the trailing twelve months.
